Investor Presentation for the quarter and year ended March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Innovassynth Technologies reported Q4FY26 revenue of Rs 5,083 lakhs with PAT of Rs 1,196 lakhs (24% margin), showing strong sequential recovery from Q3. For full year FY26, revenue stood at Rs 10,235 lakhs but PAT was negative at Rs -2,878 lakhs due to merger-related integration costs and one-time disruptions. The company attributed Q4 softness to temporary shipment delays from Middle East logistics disruptions and a one-time customer inventory adjustment, both described as transitory. The order book improved by approximately Rs 60 crore during the quarter, and the company expects improved performance in coming quarters with normalized shipment schedules. Life sciences capacity expansion is underway to double manufacturing capacity. Key customers include USA-based companies and global chemical companies, with operations primarily in USA and Europe (90% exports). FY26 and FY25 figures are not directly comparable due to merger effective October 2024.
The company showed strong Q4 recovery but full-year FY26 was loss-making due to merger integration costs and one-time disruptions. Management expects improved performance ahead as shipment schedules normalize and the expanded order book converts to revenue. The 2x capacity expansion in Life Sciences aligned with CDMO demand growth provides medium-term growth visibility.